OncoMatch/Clinical Trials/NCT06297512
Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).
Is NCT06297512 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Radiotherapy, Temozolomide, Doxorubicin for glioblastoma.
Treatment: Radiotherapy, Temozolomide, Doxorubicin — Glioblastoma (GBM) and diffuse intrinsic bridge gliomas (DIPG) only the most aggressive forms of cancer, and their prognosis remains bleak. Currently, the standard of treatment is TMZ concomitant with radiotherapy, and, at the end of combined treatment, as adjuvant therapy. In vitro and in vivo experimental studies have suggested that anthracyclines are effective antineoplastics for the treatment of gliomas. In patients with solid tumors treated with anthracyclines, continuous infusion administration compared with bolus administration has been shown to provide a better safety profile especially with regard to cardiotoxicity. Based on this evidence, this study aims to evaluate the safety and antitumor activity of combined treatment with Dox, WBRT (whole body radiotherapy), and TMZ in pediatric and young adult patients affected by GMB
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Allowed: IDH1 wild-type
IDH-wildtype glioblastoma (9440/3)
Allowed: IDH1 mutation
IDH-mutated glioblastoma (9445/3)
Allowed: H3F3A (H3 K27M) K27M
diffuse midline glioma H3 K27M mutated
Prior therapy
Must have received: surgery
treated only surgically (total, near partial, partial, biopsy)
Cannot have received: chemotherapy
Not previously treated (with chemo and radiotherapy)
Cannot have received: radiation therapy
Not previously treated (with chemo and radiotherapy)
Cannot have received: chemotherapy
Performance of a course of 1st-line chemotherapy at the same time as study initiation
Lab requirements
Blood counts
absolute leukocyte count ≥ 2.0 x 10^9/l, hemoglobin ≥ 10 g/dl, platelet count ≥ 50 x 10^9/l
Kidney function
serum creatinine ≤ 1.5 x uln
Liver function
total bilirubin ≤ 2.5 x uln, alt/ast ≤ 5.0 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify